https://www.selleckchem.com/products/azd8186.html
42, 95% CI -2.24 to -0.59; = 0.0007) and urine loss on pad test (MD -4.67, 95% CI -8.05 to -1.28; = 0.007). There were no significant treatment-related adverse reactions. This study evaluated the efficacy and safety of MS in the treatment of female SUI. The results have important implications for patients who do not wish to undergo surgical therapy. We found that MS treatment for SUI has positive outcomes, however, future studies should aim at establishing the best protocol for optimizing the therapeutic effect. This study evaluated t